Egalet Corp (EGLT) Files Form 4 Insider Selling : Jeffrey M. Dayno Sells 536 Shares

Egalet Corp (EGLT): Jeffrey M. Dayno , Chief Medical Officer of Egalet Corp sold 536 shares on Jun 30, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $4.65 per share for a total value of $2,492.40 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 6, 2016, Robert S Radie (President and CEO) sold 5,000 shares at $6.99 per share price.On Apr 6, 2016, Deanne F. Melloy (Chief Commercial Officer) sold 860 shares at $6.96 per share price.Also, On Apr 4, 2016, Stan Musial (Chief Financial Officer) sold 3,480 shares at $7.02 per share price.On Apr 4, 2016, Mark Strobeck (Chief Business Officer) sold 8,700 shares at $6.70 per share price.

Egalet Corp: On Friday, Jul 1, 2016 heightened volatility was witnessed in Egalet Corp which led to swings in the share price. The shares opened for trading at $4.94 and hit $5.17 on the upside , eventually ending the session at $5.1, with a gain of 2.82% or 0.14 points. The heightened volatility saw the trading volume jump to 1,05,904 shares. The 52-week high of the share price is $16.59 and the company has a market cap of $128 M . The 52-week low of the share price is at $4.34.

Egalet Corp Money Flow Index Chart

Egalet Corporation is a specialty pharmaceutical company developing manufacturing and commercializing medicines for patients with acute and chronic pain. The Company’s products include OXAYDO and SPRIX Nasal Spray. OXAYDO is the immediate-release oxycodone product formulated to deter abuse via snorting for the management of acute and chronic moderate to severe pain where an opioid is appropriate. SPRIX Nasal Spray is the nasal spray formulation of non-steroidal anti-inflammatory drug (NSAID) ketorolac used for short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company is developing two late-stage product candidates using Guardian Technology. The lead program Egalet-001 is an abuse-deterrent extended-release oral morphine formulation and Egalet-002 is an abuse-deterrent extended-release oral oxycodone formulation.

Leave a Reply

Egalet Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Egalet Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.